{"disease":{"id":"upper-limb-spasticity","name":"Upper limb spasticity","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in pediatric patients (excluding cerebral palsy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"botulinum-toxin-type-a","indication_name":"Upper limb spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuceiva","generic_name":"BOTULINUM TOXIN TYPE A","company_name":"GlaxoSmithKline K.K.","drug_phase":"marketed","molecular_target":"Synaptosomal-associated protein 25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions."},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04936542","title":"A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":464,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT07478822","title":"A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Chongqing Claruvis Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06783114","title":"A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":254,"lead_sponsor_name":"Chongqing Claruvis Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05289921","title":"To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Huons Co., Ltd.","has_results":false},{"nct_id":"NCT04604379","title":"A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal Spasticity","phase":"","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT05224349","title":"Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.","phase":"","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT06584240","title":"A Clinical Study to Evaluate the Safety and Efficacy of JHM03 in Adult Patients With Upper Limb Spasticity","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"JHM BioPharma (Tonghua) Co. , Ltd.","has_results":false},{"nct_id":"NCT03821402","title":"Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07340034","title":"Effects of Focal Muscle Vibration Versus Whole Upper Limb Vibration in Post-Stroke Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Lahore University of Biological and Applied Sciences","has_results":false},{"nct_id":"NCT03131791","title":"Comparing the Radial Extracorporeal Shock Waves and Botulinum Toxin Injection for Spasticity","phase":"NA","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Mackay Memorial Hospital","has_results":false},{"nct_id":"NCT06674057","title":"Additional Effects of Kinesio-Taping Along with Conservative Physical Therapy on Upper Limb Function, Range of Motion and Spasticity in the Patients with Subacute Stroke","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Foundation University Islamabad","has_results":false},{"nct_id":"NCT05940805","title":"Comprehensive Protocol for Treatment of Upper Limb Spasticity in Post-stroke Hemiplegic Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT07292025","title":"Phase 1 Trial of JTM201 in Subjects With Post-stroke Upper Limb Spasticity","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Jetema Co., Ltd.","has_results":false},{"nct_id":"NCT05382767","title":"Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"CKD Bio Corporation","has_results":false},{"nct_id":"NCT05169775","title":"A Single Centre, Prospective, Observational Study to Assess the Use of the Rehabilitation Tool, GripAble, in Patients With Upper Limb Spasticity Receiving Botulinum Toxin-A (BoNT-A) in the United Kingdom (UK).","phase":"","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT05956509","title":"Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"AbbVie","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}